These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1027 related items for PubMed ID: 21757253

  • 1. ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity.
    Kimura H, Nakajima T, Takeuchi K, Soda M, Mano H, Iizasa T, Matsui Y, Yoshino M, Shingyoji M, Itakura M, Itami M, Ikebe D, Yokoi S, Kageyama H, Ohira M, Nakagawara A.
    Lung Cancer; 2012 Jan; 75(1):66-72. PubMed ID: 21757253
    [Abstract] [Full Text] [Related]

  • 2. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.
    Dubey AP, Pathi N, Viswanath S, Rathore A, Pathak A, Sud R.
    Indian J Cancer; 2017 Jan; 54(1):203-208. PubMed ID: 29199691
    [Abstract] [Full Text] [Related]

  • 3. A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene.
    Isozaki H, Yasugi M, Takigawa N, Hotta K, Ichihara E, Taniguchi A, Toyooka S, Hashida S, Sendo T, Tanimoto M, Kiura K.
    Jpn J Clin Oncol; 2014 Oct; 44(10):963-8. PubMed ID: 25170107
    [Abstract] [Full Text] [Related]

  • 4. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F.
    Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
    [Abstract] [Full Text] [Related]

  • 5. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
    Cha YJ, Kim HR, Shim HS.
    J Transl Med; 2016 Oct 19; 14(1):296. PubMed ID: 27756333
    [Abstract] [Full Text] [Related]

  • 6. EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.
    Wu SG, Kuo YW, Chang YL, Shih JY, Chen YH, Tsai MF, Yu CJ, Yang CH, Yang PC.
    J Thorac Oncol; 2012 Jan 19; 7(1):98-104. PubMed ID: 22124476
    [Abstract] [Full Text] [Related]

  • 7. EML4-ALK fusion gene assessment using metastatic lymph node samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration.
    Sakairi Y, Nakajima T, Yasufuku K, Ikebe D, Kageyama H, Soda M, Takeuchi K, Itami M, Iizasa T, Yoshino I, Mano H, Kimura H.
    Clin Cancer Res; 2010 Oct 15; 16(20):4938-45. PubMed ID: 20926401
    [Abstract] [Full Text] [Related]

  • 8. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
    Toyokawa G, Seto T.
    Respir Investig; 2014 Nov 15; 52(6):330-8. PubMed ID: 25453376
    [Abstract] [Full Text] [Related]

  • 9. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing.
    Wallander ML, Geiersbach KB, Tripp SR, Layfield LJ.
    Arch Pathol Lab Med; 2012 Jul 15; 136(7):796-803. PubMed ID: 22742552
    [Abstract] [Full Text] [Related]

  • 10. ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.
    Alì G, Proietti A, Pelliccioni S, Niccoli C, Lupi C, Sensi E, Giannini R, Borrelli N, Menghi M, Chella A, Ribechini A, Cappuzzo F, Melfi F, Lucchi M, Mussi A, Fontanini G.
    Arch Pathol Lab Med; 2014 Nov 15; 138(11):1449-58. PubMed ID: 24885803
    [Abstract] [Full Text] [Related]

  • 11. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers.
    Inamura K, Takeuchi K, Togashi Y, Nomura K, Ninomiya H, Okui M, Satoh Y, Okumura S, Nakagawa K, Soda M, Choi YL, Niki T, Mano H, Ishikawa Y.
    J Thorac Oncol; 2008 Jan 15; 3(1):13-7. PubMed ID: 18166835
    [Abstract] [Full Text] [Related]

  • 12. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
    Ma D, Wang Z, Yang L, Mu X, Wang Y, Zhao X, Li J, Lin D.
    Oncotarget; 2016 Sep 27; 7(39):64410-64420. PubMed ID: 27418132
    [Abstract] [Full Text] [Related]

  • 13. A novel KIF5B-ALK variant in nonsmall cell lung cancer.
    Wong DW, Leung EL, Wong SK, Tin VP, Sihoe AD, Cheng LC, Au JS, Chung LP, Wong MP.
    Cancer; 2011 Jun 15; 117(12):2709-18. PubMed ID: 21656749
    [Abstract] [Full Text] [Related]

  • 14. Effective enrichment strategy for EML4-ALK fusion gene screening in patients with non-small cell lung cancer.
    Kobayashi M, Sakakibara T, Inoue A, Fukuhara T, Sasano H, Ichinose M, Nukiwa T.
    Respir Investig; 2014 Jan 15; 52(1):49-56. PubMed ID: 24388371
    [Abstract] [Full Text] [Related]

  • 15. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
    Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ.
    N Engl J Med; 2010 Oct 28; 363(18):1693-703. PubMed ID: 20979469
    [Abstract] [Full Text] [Related]

  • 16. Identification and characterization of ALK kinase splicing isoforms in non-small-cell lung cancer.
    de Figueiredo-Pontes LL, Wong DW, Tin VP, Chung LP, Yasuda H, Yamaguchi N, Nakayama S, Jänne PA, Wong MP, Kobayashi SS, Costa DB.
    J Thorac Oncol; 2014 Feb 28; 9(2):248-53. PubMed ID: 24419423
    [Abstract] [Full Text] [Related]

  • 17. Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer.
    Tiseo M, Gelsomino F, Bartolotti M, Bordi P, Bersanelli M, Rossi G, Ardizzoni A.
    Expert Rev Anticancer Ther; 2011 Nov 28; 11(11):1677-87. PubMed ID: 22050016
    [Abstract] [Full Text] [Related]

  • 18. miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC.
    Lai Y, Kacal M, Kanony M, Stukan I, Jatta K, Kis L, Norberg E, Vakifahmetoglu-Norberg H, Lewensohn R, Hydbring P, Ekman S.
    Biochem Biophys Res Commun; 2019 Apr 02; 511(2):260-265. PubMed ID: 30791979
    [Abstract] [Full Text] [Related]

  • 19. Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan.
    Wu YC, Chang IC, Wang CL, Chen TD, Chen YT, Liu HP, Chu Y, Chiu YT, Wu TH, Chou LH, Chen YR, Huang SF.
    PLoS One; 2013 Apr 02; 8(8):e70839. PubMed ID: 23951022
    [Abstract] [Full Text] [Related]

  • 20. Immunohistochemistry, fluorescence in situ hybridization, and reverse transcription-polymerase chain reaction for the detection of anaplastic lymphoma kinase gene rearrangements in patients with non-small cell lung cancer: potential advantages and methodologic pitfalls.
    Demidova I, Barinov A, Savelov N, Gagarin I, Grinevitch V, Stroiakovaski D, Popov M, Laktionov K, Gutorov S, Smolin A, Olshanskaya Y, Obukhova T.
    Arch Pathol Lab Med; 2014 Jun 02; 138(6):794-802. PubMed ID: 24878018
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 52.